Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
PMID: Summary Keywords cardiovascular outcomes, end-stage renal disease, chronic kidney disease, glucagon-like peptide-1 receptor agonists, hemodialysis, real-world evidence, semaglutide, type 2 diabetes mellitus Citation Alkhezi O, Alfehaid L, Alanezi A, Alotaibi M and Alshaya O (2026) Real-world use of semaglutide in patients with type 2 diabetes and end-stage renal disease: a multicenter retrospective cohort study
You can explore the full range of treatment options at Your treatment plan should reflect your individual circumstances, not a cookie-cutter approach
A few years ago, almost nobody outside an endocrinologists office could pronounce semaglutide. Today it feels like every other conversation circles back to it
This is likely why retatrutides triple agonism works so well: it captures glucagons metabolic and lipid effects without causing high blood sugar
